Audio: Zacks.com Bull and Bear of the Week

Charles Rotblut, senior market analyst for Zacks.com, said that the potential for a better merger deal with Roche makes Genentech the "Bull of the Week." Rotblut noted that Genentech rejected Roche's first offer of $89 per share, but Zacks expects a... 3 months ago